Vor Biopharma Inc (VOR): Next-Year EPS Estimate 46.39%
As of 2026-06-04, Vor Biopharma Inc (VOR) has a next-year EPS growth estimate of 46.39%.
On 2026-05-18, analyst consensus for VOR's next-year EPS growth shifted from 42.21% to 46.39% — a positive change of 4.18 percentage points. The revised estimate has been sustained across 14 subsequent trading sessions. Current-year growth is projected at 90.78%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 46.39%
- EPS growth this year
- 90.78%
- EPS next quarter (est)
- -$0.70
- Last price
- $14.32
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 46.39% | 90.78% | -$0.70 | $14.32 |
| 2026-06-03 | 46.39% | 90.78% | -$0.70 | $13.44 |
| 2026-06-02 | 46.39% | 90.78% | -$0.70 | $13.66 |
| 2026-06-01 | 46.39% | 90.78% | -$0.70 | $14.57 |
| 2026-05-31 | 46.39% | 90.78% | -$0.70 | $14.97 |
| 2026-05-28 | 46.39% | 90.78% | -$4.99 | $15.01 |
| 2026-05-27 | 46.39% | 90.78% | -$4.99 | $15.52 |
| 2026-05-26 | 46.39% | 90.78% | -$4.99 | $14.10 |
| 2026-05-25 | 46.39% | 90.78% | -$4.99 | $14.33 |
| 2026-05-24 | 46.39% | 90.78% | -$4.99 | $14.33 |
| 2026-05-21 | 46.39% | 90.78% | -$4.99 | $15.04 |
| 2026-05-20 | 46.39% | 90.78% | -$4.99 | $15.55 |
| 2026-05-19 | 46.39% | 90.78% | -$4.99 | $14.13 |
| 2026-05-18 | 46.39% | 90.78% | -$4.99 | $14.13 |
| 2026-05-17 | 42.21% | 91.34% | -$4.04 | $14.63 |
| 2026-05-14 | 36.75% | 91.91% | -$3.55 | $15.07 |
| 2026-03-31 | 95.64% | N/A | N/A | $17.84 |
| 2026-03-30 | 94.08% | N/A | N/A | $14.70 |
| 2026-03-30 | 97.35% | N/A | N/A | $14.70 |
| 2026-03-30 | 97.16% | N/A | N/A | $14.70 |
| 2026-03-29 | 94.08% | N/A | N/A | $14.48 |
| 2026-03-29 | 94.08% | N/A | N/A | $14.48 |
| 2026-03-27 | 95.64% | N/A | N/A | $14.48 |
| 2026-03-26 | 94.08% | N/A | N/A | $13.57 |
| 2026-03-26 | 95.64% | N/A | N/A | $13.57 |
| 2026-03-26 | 95.64% | N/A | N/A | $13.57 |
| 2026-03-25 | 94.08% | N/A | N/A | $12.94 |
| 2026-03-25 | 95.64% | N/A | N/A | $12.94 |
| 2026-03-25 | 95.64% | N/A | N/A | $12.94 |
| 2026-03-24 | 94.08% | N/A | N/A | $12.15 |
Recent News
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineGlobeNewswire
- Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjogren's DiseaseGlobeNewswire
- Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjogren's DiseaseGlobeNewswire
- Vor Bio Announces $75 Million Private Placement with TCGXGlobeNewswire
- Vor Bio Announces $75 Million Private Placement with TCGXGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Vor Biopharma Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Vor Biopharma Inc (VOR) has a next-year EPS growth estimate of 46.39%, based on analyst consensus.
When was the latest EPS estimate revision for VOR?▾
The most recent revision occurred on 2026-05-18, when analysts adjusted the next-year EPS growth estimate from 42.21% to 46.39%.
What sector and industry does Vor Biopharma Inc belong to?▾
Vor Biopharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. VOR appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Vor Biopharma Inc (VOR) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports